Skip to main content
MedPathMedPath Home
Clinical Trials/RPCEC00000266
RPCEC00000266
Not yet recruiting
Phase 1

Phase I / II study of dose escalation and expansion to cohorts, with the therapeutic antibody 14F7h (Anti-NGlicolilGM3) in patients with chronic B-cell lymphoproliferative syndrome, refractory or relapsing

Center of Molecular Immunology (CIM)0 sites142 target enrollmentMarch 7, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionson-Hodgkin lymphoma, Chronic lymphocytic leukemia, Multiple myeloma

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
on-Hodgkin lymphoma, Chronic lymphocytic leukemia, Multiple myeloma
Sponsor
Center of Molecular Immunology (CIM)
Enrollment
142
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 7, 2018
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Center of Molecular Immunology (CIM)

Eligibility Criteria

Inclusion Criteria

  • •1\. Refractory or relapsing B\-cell cell lymphoproliferative syndrome, ganglioside NGlicolilGM3 (NGGM3\) positive.
  • •2\. Age \=18 years, any gender and race.
  • •3\. ECOG \= 3\.
  • •4\. Life expectancy of 6 months.
  • •5\. No candidates for transplant of hematopoietic progenitors or immunochemotherapy schemes not previously used.
  • •6\. Four or more weeks from the previous specific therapy (QT, RT, biological therapies) (applicable to patients’ refractory to the previous treatment).
  • •7\. Patients with laboratory parameters as detailed below: Hemoglobin \= 80 g / L, Absolute neutrophil count \= 1\.5 x 109 / L, Platelet count \= 75 x 109 / L, Liver function (bilirubin, ASAT or ALAT \= 2\.5 times the normal reference range of each institution), Renal function preserved (creatinine clearance \=45 mL / min according to the Cockcroft and Gault formula).
  • •8\. Voluntary signature of the informed consent model.
  • •9\. Subjects of childbearing age and sexually active should agree to use a method of contraception during treatment (criteria valid only for patients of childbearing age).

Exclusion Criteria

  • •1\. Pregnant, puerperal or breastfeeding
  • •2\. Cytopenia of uncontrolled immune cause
  • •3\. Active infection or known positivity for HIV, hepatitis B or C virus
  • •4\. Heart failure grade III / IV according to NYHA criteria (New York Heart Association)
  • •5\. Chronic decompensated diseases such as: arterial hypertension, diabetes mellitus, ischemic cardiopathy or other symptomatic cardiovascular diseases, epilepsy, obstructive pulmonary disease.
  • •6\. Acute allergic states or known hypersensitivity to any component of the formulation under study.
  • •7\. Obvious mental disability or other limitation that prevents the patient from signing their consent or hinders the evaluation of the study.
  • •8\. Being receiving another research product.
  • •9\. Another clinically active neoplasm that needs specific treatment (except basal cell carcinomas or cutaneous carcinomas in situ).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Clinical trial using GSK525762 in combination with fulvestrant in subjects with breast cancer.ER-positive Breast CancerMedDRA version: 20.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000115074Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-003074-40-FRGlaxoSmithKline Research & Development Limited123
Active, not recruiting
Phase 1
Study investigation GSK525762 in combination with fulvestrant in treatments of breast cancer.ER-positive Breast CancerMedDRA version: 19.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-003074-40-ESGlaxoSmithKline Research & Development Limited300
Active, not recruiting
Phase 1
Clinical trial using GSK525762 in combination with fulvestrant in subjects with breast cancer.ER-positive Breast CancerMedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-003074-40-GBGlaxoSmithKline Research & Development Limited300
Active, not recruiting
Phase 1
Study to evaluate the effectiveness, safety and tolerability of nivolumab in subjects with advanced liver cancer.Hepatocellular carcinomaMedDRA version: 19.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-001514-42-DEBristol-Myers Squibb International Corporation570
Active, not recruiting
Phase 1
Study to evaluate the effectiveness, safety and tolerability of nivolumab in subjects with advanced liver cancer.Hepatocellular carcinomaMedDRA version: 20.0 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrent System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectable System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-001514-42-GBBristol-Myers Squibb International Corporation570